Cargando…

Individual Treatment Decisions for Central Neurocytoma

Objective: Central neurocytomas (CNs) are rare, and this has resulted in a paucity of information and a lack of clarity regarding their optimal management. This study aimed to explore individual treatment strategies for CNs and the benefits of these strategies for patients. Methods: This single-cent...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Song, Yang, Zuocheng, Yang, Yakun, Qi, Xueling, Yan, Changxiang, Yu, Chunjiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457043/
https://www.ncbi.nlm.nih.gov/pubmed/32922351
http://dx.doi.org/10.3389/fneur.2020.00834
_version_ 1783575921729470464
author Han, Song
Yang, Zuocheng
Yang, Yakun
Qi, Xueling
Yan, Changxiang
Yu, Chunjiang
author_facet Han, Song
Yang, Zuocheng
Yang, Yakun
Qi, Xueling
Yan, Changxiang
Yu, Chunjiang
author_sort Han, Song
collection PubMed
description Objective: Central neurocytomas (CNs) are rare, and this has resulted in a paucity of information and a lack of clarity regarding their optimal management. This study aimed to explore individual treatment strategies for CNs and the benefits of these strategies for patients. Methods: This single-center study retrospectively analyzed data from 67 patients with CNs who underwent surgery. Based on the extent of resection, patients were divided into complete and incomplete resection groups. The patients were followed, and overall survival (OS) and progression-free survival (PFS) were determined. Results: Of 55 patients (82.1%) who underwent complete resections, 24 received radiotherapy (24/55, 43.6%). Of 12 patients who underwent incomplete resections, 9 (9/12, 75.0%) received radiotherapy. The OS (p = 0.003) and PFS (p = 0.006) intervals were significantly longer in the complete resection group than in the incomplete resection group. Postoperative radiotherapy did not affect OS (p = 0.129) or PFS (p = 0.233) in the complete resection group. In the incomplete resection group, postoperative adjuvant radiotherapy prolonged patient survival significantly (p = 0.021). PFS was significantly longer among patients who underwent complete resection without radiotherapy than in those who underwent incomplete resection followed by radiotherapy (p = 0.034). Functional dependence on admission, which was defined as a Karnofsky Performance Status score <70, was an independent risk factor associated with long-term survival in patients with CN. Postoperative complications were not associated with the amount of tumor resected. The prognosis of patients aged ≥ 50 years was relatively poor. The atypical CN recurrence rate was relatively high (7.8%). Conclusions: To protect function as much as possible, complete tumor resection should be the first choice of treatment for CN. After gross total resection, adjuvant radiotherapy is not acceptable. Postoperative adjuvant radiotherapy improves the prognosis of patients who have undergone incomplete tumor resections. Adjuvant radiotherapy is not recommended after complete resections of atypical CNs, and close follow-up with imaging is required. Our findings can help guide decision-making regarding the treatment of CNs and could potentially maximize the benefits of treatment for patients with CN.
format Online
Article
Text
id pubmed-7457043
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-74570432020-09-11 Individual Treatment Decisions for Central Neurocytoma Han, Song Yang, Zuocheng Yang, Yakun Qi, Xueling Yan, Changxiang Yu, Chunjiang Front Neurol Neurology Objective: Central neurocytomas (CNs) are rare, and this has resulted in a paucity of information and a lack of clarity regarding their optimal management. This study aimed to explore individual treatment strategies for CNs and the benefits of these strategies for patients. Methods: This single-center study retrospectively analyzed data from 67 patients with CNs who underwent surgery. Based on the extent of resection, patients were divided into complete and incomplete resection groups. The patients were followed, and overall survival (OS) and progression-free survival (PFS) were determined. Results: Of 55 patients (82.1%) who underwent complete resections, 24 received radiotherapy (24/55, 43.6%). Of 12 patients who underwent incomplete resections, 9 (9/12, 75.0%) received radiotherapy. The OS (p = 0.003) and PFS (p = 0.006) intervals were significantly longer in the complete resection group than in the incomplete resection group. Postoperative radiotherapy did not affect OS (p = 0.129) or PFS (p = 0.233) in the complete resection group. In the incomplete resection group, postoperative adjuvant radiotherapy prolonged patient survival significantly (p = 0.021). PFS was significantly longer among patients who underwent complete resection without radiotherapy than in those who underwent incomplete resection followed by radiotherapy (p = 0.034). Functional dependence on admission, which was defined as a Karnofsky Performance Status score <70, was an independent risk factor associated with long-term survival in patients with CN. Postoperative complications were not associated with the amount of tumor resected. The prognosis of patients aged ≥ 50 years was relatively poor. The atypical CN recurrence rate was relatively high (7.8%). Conclusions: To protect function as much as possible, complete tumor resection should be the first choice of treatment for CN. After gross total resection, adjuvant radiotherapy is not acceptable. Postoperative adjuvant radiotherapy improves the prognosis of patients who have undergone incomplete tumor resections. Adjuvant radiotherapy is not recommended after complete resections of atypical CNs, and close follow-up with imaging is required. Our findings can help guide decision-making regarding the treatment of CNs and could potentially maximize the benefits of treatment for patients with CN. Frontiers Media S.A. 2020-08-12 /pmc/articles/PMC7457043/ /pubmed/32922351 http://dx.doi.org/10.3389/fneur.2020.00834 Text en Copyright © 2020 Han, Yang, Yang, Qi, Yan and Yu. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Han, Song
Yang, Zuocheng
Yang, Yakun
Qi, Xueling
Yan, Changxiang
Yu, Chunjiang
Individual Treatment Decisions for Central Neurocytoma
title Individual Treatment Decisions for Central Neurocytoma
title_full Individual Treatment Decisions for Central Neurocytoma
title_fullStr Individual Treatment Decisions for Central Neurocytoma
title_full_unstemmed Individual Treatment Decisions for Central Neurocytoma
title_short Individual Treatment Decisions for Central Neurocytoma
title_sort individual treatment decisions for central neurocytoma
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457043/
https://www.ncbi.nlm.nih.gov/pubmed/32922351
http://dx.doi.org/10.3389/fneur.2020.00834
work_keys_str_mv AT hansong individualtreatmentdecisionsforcentralneurocytoma
AT yangzuocheng individualtreatmentdecisionsforcentralneurocytoma
AT yangyakun individualtreatmentdecisionsforcentralneurocytoma
AT qixueling individualtreatmentdecisionsforcentralneurocytoma
AT yanchangxiang individualtreatmentdecisionsforcentralneurocytoma
AT yuchunjiang individualtreatmentdecisionsforcentralneurocytoma